Biogen Inc. (NASDAQ:BIIB) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference operator today. At this time, I’d like to welcome everyone to the Biogen Fourth Quarter and Full Year 2024 Earnings Call and Business Update.
What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday?
Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street forecasts fourth-quarter adjusted EPS of $3.35 and sales of $2.40 billion, while fiscal year 2024 adjusted EPS is expected to be $16.
Biogen (BIIB) Q4 2024 Earnings Call Transcript
At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I would now like to turn the conference over to Mr.
Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates
Biogen Inc. (BIIB) came out with quarterly earnings of $3.44 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $2.95 per share a year ago. These figures are adjusted for non-recurring items.
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints
Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate of $3.42. Earnings rose 17% year over year on a reported basis, boosted by the company’s cost-cutting efforts.
Earnings call transcript: Biogen Q4 2024 EPS beats estimates, stock drops
Biogen Inc. (NASDAQ:BIIB), currently valued at $19.15 billion by market capitalization, reported its earnings for the fourth quarter of 2024, surpassing analysts' expectations with a non-GAAP diluted earnings per share (EPS) of $3.
Biogen’s (NASDAQ:BIIB) Q4 Sales Top Estimates
Biotech company Biogen (NASDAQ:BIIB) reported in Q4 CY2024, with sales up 2.9% year on year to $2.45 billion. Its non-GAAP profit of $3.44 per share was 2.3% above analysts’ consensus estimates. Is now the time to buy Biogen?
Piper Sandler Remains a Hold on Biogen (BIIB)
Piper Sandler analyst David Amsellem maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $138.00. The ...
Biogen Analysts Lower Their Forecasts After Q4 Results
The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales ...
Biogen (NASDAQ:BIIB) Stock Price Down 6.8% Following Analyst Downgrade
Biogen Inc. (NASDAQ:BIIB – Get Free Report) traded down 6.8% during trading on Wednesday after Bank Of America (Bofa) lowered ...
Biogen (BIIB) Gets a Buy from Mizuho Securities
Mizuho Securities analyst Salim Syed maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $207.00.
Biogen outlook disappoints amid pressure on multiple sclerosis franchise
Biogen (NASDAQ:BIIB) stock traded flat as the company reports better than expected Q4 2024 financials, but its 2025 outlook ...
Cowen cuts Biogen stock price target to $200, maintains Buy rating
TD Cowen analysts adjusted their outlook on Biogen (NASDAQ:BIIB) shares, reducing the price target to $200 from the previous $275, while sustaining a Buy rating on the stock. The revision reflects ...
Yahoo Finance4d
Why Biogen Inc. (BIIB) Is Among the Best Healthcare Stocks To Buy According to Analysts
In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry witnessed ...
Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...
Biogen (BIIB) Receives a Buy from Scotiabank
In a report released today, George Farmer from Scotiabank maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...